Biocytogen is excited to attend and deliver oral and poster presentations at the upcoming 14th World ADC London conference, held on March 13th-14th, 2024!
Dr. Yi (Benny) Yang, Chief Scientific Officer of Biocytogen, will give an oral presentation entitled “RenBiologics is at the forefront of advancing bispecific ADCs and nanobody ADCs” in the Discovery Stream session on March 13th. In the session, Dr. Yang will
- Introduce Biocytogen’s state-of-the-art in vivo antibody discovery engines, featuring RenMabTM, RenLite®, and RenNano® mice, alongside a unique collection of 400k+ fully-human antibody binders validated for about 1000 human targets.
- Showcase Biocytogen’s innovative plug-and-play strategy for developing novel bispecific ADC programs.
In addition, Biocytogen’s antibody Business Development & Licensing team will present 2 posters, introducing our bispecific ADC asset BCG033 (PTK7 x TROP2 bsADC) and our tumor-associated antigen (TAA) antibody library, consisting of antibodies against approximately 200 targets with a proprietary linker/payload for ADC plug-and-play.
- A Novel PTK7 x TROP2 bispecific ADC, BCG033, demonstrates potent efficacy against TNBC and other tumor xenografts
- The TAA antibody library from RenBiologics: advancing innovation in the field of antibody-drug-conjugates (ADCs)
We look forward to discussing licensing and co-development opportunities with you! Contact us at BD-Licensing@biocytogen.com to schedule a meeting with us.
About the speaker
Dr. Yi (Benny) Yang,
Chief Scientific Officer of Biocytogen
Dr. Yang graduated from Fudan University with a Master’s degree in Microbiology. He received his Ph.D. degree in Immunology from University of Connecticut Health Center (UCHC) and completed his postdoctoral training at New York University School of Medicine in Dr. Dan Littman’s research group. Then Dr. Yang was recruited to the Medical University of South Carolina (MUSC) as a tenure-track Assistant Professor at the Department of Microbiology and Immunology. In 2016, he joined Biocytogen and has been leading the antibody drug discovery.
About Biocytogen:
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMabTM/RenLite®/RenNano®/RenTCR-mimicTM) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologicsTM, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets. As of Dec.31, 2023, 103 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 47 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMiceTM, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
Biocytogen’s Contacts
Antibody assets and platforms: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn
